DSP-0390 is under clinical development by Sumitomo Pharma and currently in Phase II for Oligodendroglioma. According to GlobalData, Phase II drugs for Oligodendroglioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the DSP-0390 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DSP-0390 is under development for the treatment of solid tumor, brain cancer and recurrent high grade glioma, recurrent malignant glioma, anaplastic astrocytoma and anaplastic oligodendroglioma, brain cancer recurrent glioblastoma multiforme. It acts by targeting EBP (Emopamil Binding Protein). It is administered through oral route. The drug candidate is a new chemical entity.
Sumitomo Pharma overview
Sumitomo Pharma, formerly Sumitomo Dainippon Pharma Co Ltd, develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. The company offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Pharma has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Chuo-ku, Osaka, Japan.
For a complete picture of DSP-0390’s drug-specific PTSR and LoA scores, buy the report here.